Trial Profile
An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Apellis Pharmaceuticals
- 23 Feb 2024 The trial has been completed in France, according to European Clinical Trials Database record.
- 12 Dec 2023 Results of an integrated analysis assessing long-term efficacy and safety of pegcetacoplan for PNH treatment from following clinical trials: PEGASUS, PRINCE and their extension trials presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Dec 2023 According to an Apellis Pharmaceuticals media release, post hoc data from PEGASUS and PRINCE studies and the long-term extension study that reinforce the long-term efficacy and safety of EMPAVELI were presented during an oral presentation at the American Society of Hematology (ASH) Annual Meeting.